Exon-19 deletions (19del) and L858R substitution in exon-21 are the 2 classical EGFR mutations which could predict tumor responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients [6–10]. Here, EGFR is linked to neoplasm.